They will never understand this.......don't waste your time!!!
With you that tell ypu some of the stories of your long time faithful supporters. Some have invested their time, some have invested their money(most have invested both) and some have sadly passed from this earth not knowing what the end of the story will be. For the patients, for the stakeholders, and for all who have supported the ompany and fought for Provenge, please keep them informed of events within , of your ongoing governance and if the future.
Please do not forget the small stakeholders and their importance to you effort and advancement of the field of immunotherapy. We look forward to many more years of continued development.
Kerry M, Donahue
Disclosures cannot and should not be shared with investors individually, that does not mean that questions and requests are irrelevant and should not be considered. Be it by press release, investor PR, or other mechanism, transparency and communication should become a much higher prong in your hierarchy of priorities
Yours is no ordinary company. Never in the history of biotech has the voice of the small stakeholder been so loud, so proud and meant so much. Hundreds if not thousands took to the Internet, to the press, to the courts, to the government, to the roof tops, and demanded justice as they fought for our first approved immunotherapy, Provenge. There was a PR war like few have ever seen being waged, not by Dendreon and it's employees( and no disrespect meant to the employees that worked so hard) but by the small stakeholder. While the actiivism of the Dendreon stakeholders has diminished along with their "fortunes", the fight continues, apparently unabated by defining silence of the Company.
Having invested their time and their money in what has been a long journey I do not think that it is too much for you to keep them informed. How can bad information be fought with no information?
On behalf of myself and the stakeholders I would ask you to keep us informed. Again I cite to the Board Principles of Goverance as a reminder of your duties:
The Corporate Governance Committee will undertake annually to engage the Board in an evaluation of the Boards performance, including a discussion of the results of this evaluation in a meeting with the full Board. This evaluation is to include consideration of the Board's contribution as a whole and constructive feedback and suggestions for improvement. Each of the Corporate Governance Committee, Audit Committee, and Compensation Committee assesses the adequacy of its charter annually and recommends changes to the Board as appropriate.
Attached to this letter are letters that have been provided for me to share
The view has not changed, patients first, including continued education of patients and the medical community of the first ever approved immunotherapy and distribution of Provenge to as many patients as possible, as early as possible in their treatment regime, so as to best help them in their fight against Prostate Cancer. In addition, the ability to continue pipeline research of research of immunotherapies and their application to other types of cancer remains important to all.
Throughout our 6 year fight, we fought for transparency. Transparency appears to be very much missing from this company's current strategy. We think this is wrong.
The board of Dendreon is supposed to meet four times a year. from the Corporate Governance Pronciples is the following:
The Board shall hold at least four regularly scheduled meetings each year. Scheduled meetings of each standing Board committee will vary depending on the committee's responsibilities and duties. In preparation for each regular Boatd meeting, with direction from the Chairman of the Board and the Chief Executive Officer,an agenda for the meeting and any information or material for review will be sent to the directors for consideration. In exercise of his or her duty, each director is expected to regularly attend and actively participate in Board meetings and meetings of those Board committees of which a member. Directors shall undertake to attend Dendreons annual meeting of stockholders. Each director should review prepared Board materials in advance, and facilitate discussion of matters brought before the Board in order to bring his or her knowledge and experience to bear on the issues discussed.
With those principles in mind, there would necessarily have to be much activity within Dendreon that is not being disclosed. Both myself and others share frustration with non-response made by inquiries to Dendreon in general and to its investors relations division. While we understand that certain
Couldn't post it.....so typed it here.
This letter came from Bellinger & Donahue law firm.
Addressed to Amick and Watson
Thank you for allowing me this opportunity in the middle of Prostate Cancer awareness month, to appeal to your judgement.
As you know, I acted as counsel for the group Care To Live, who helped lead the fight against injustices that were that were heaved upon Dendreon and Provenge by hedge funds, billionaire investors, unethical journalists and various government officials. As you probably also know, much of our fight was supported and otherwise assisted not only by patients and other patient advocacy groups, but also by a very large number of small stakeholders in Dendreon. While it seems over the years that Dendreon has taken care to keep large institutional investors well informed, including invites to the company plant tours, etcetera, it seems as though the small stakeholder, who has been the real long term foundation of this mop any has been long forgotten.
And yet he cannot even close the AGN deal. IMO......he's a pompous .....